|
Burkitt Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The levels of Ki67, LSH, 5-hmC, and E2F1 were all increased in germinal center B-cell lymphomas when compared with those in normal lymph nodes, and LSH was highly expressed in diffuse large B-cell lymphomas (DLBCLs) and Burkitt lymphomas (BLs) that were positive for Epstein-Barr virus (EBV) infection, indicating that LSH is linked to EBV infection in DLBCL and BL.
|
30964110 |
2019 |
|
Medulloblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Elucidation of HELLS as one of the downstream effectors of the SHH pathway may lead to novel targets for precision therapeutics with the promise of better outcomes for SHH medulloblastoma patients.
|
31541170 |
2019 |
|
B-Cell Lymphomas
|
0.010 |
Biomarker
|
group |
BEFREE |
These findings indicate a critical role for LSH as a biomarker and therapeutic target in follicular germinal center B-cell lymphoma.
|
30964110 |
2019 |
|
Diffuse Large B-Cell Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The levels of Ki67, LSH, 5-hmC, and E2F1 were all increased in germinal center B-cell lymphomas when compared with those in normal lymph nodes, and LSH was highly expressed in diffuse large B-cell lymphomas (DLBCLs) and Burkitt lymphomas (BLs) that were positive for Epstein-Barr virus (EBV) infection, indicating that LSH is linked to EBV infection in DLBCL and BL.
|
30964110 |
2019 |
|
Epstein-Barr Virus Infections
|
0.010 |
Biomarker
|
group |
BEFREE |
The levels of Ki67, LSH, 5-hmC, and E2F1 were all increased in germinal center B-cell lymphomas when compared with those in normal lymph nodes, and LSH was highly expressed in diffuse large B-cell lymphomas (DLBCLs) and Burkitt lymphomas (BLs) that were positive for Epstein-Barr virus (EBV) infection, indicating that LSH is linked to EBV infection in DLBCL and BL.
|
30964110 |
2019 |
|
Childhood Medulloblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Elucidation of HELLS as one of the downstream effectors of the SHH pathway may lead to novel targets for precision therapeutics with the promise of better outcomes for SHH medulloblastoma patients.
|
31541170 |
2019 |
|
Adult Medulloblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Elucidation of HELLS as one of the downstream effectors of the SHH pathway may lead to novel targets for precision therapeutics with the promise of better outcomes for SHH medulloblastoma patients.
|
31541170 |
2019 |
|
Autoimmune Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Our data support a contributory role of altered methylation mechanisms in the pathogenesis of systemic autoimmune disorders and related lymphoproliferative processes and suggest that LSH and DNMT3A should be investigated as candidate upstream mediators of decreased L1 promoter methylation and increased L1 expression.
|
29074164 |
2018 |
|
Lupus Erythematosus, Systemic
|
0.010 |
Biomarker
|
disease |
BEFREE |
A significant negative correlation was observed between expression of L1 and lymphoid-specific helicase (LSH, encoded by HELLS) in both SS MSG and SLE kidney tissues, as well as between DNMT3A transcripts and L1 expression in SLE kidney tissues and PBMCs.
|
29074164 |
2018 |
|
Osteosarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Further, we pioneered the study of <i>Hells</i> in developmental tumor models by generating Hells conditional knockout osteosarcoma mouse models to examine the role of HELLS in osteosarcoma tumor development.
|
30220967 |
2018 |
|
Primary Sjögren's syndrome
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Reduced levels of L1 promoter methylation along with increased DNMT3B, DNMT1, and MeCP2, but reduced LSH levels were detected in SS-low risk patients compared to both SS-lymphoma and SC.
|
29074164 |
2018 |
|
Osteosarcoma of bone
|
0.010 |
Biomarker
|
disease |
BEFREE |
Further, we pioneered the study of <i>Hells</i> in developmental tumor models by generating Hells conditional knockout osteosarcoma mouse models to examine the role of HELLS in osteosarcoma tumor development.
|
30220967 |
2018 |
|
Childhood Osteosarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Further, we pioneered the study of <i>Hells</i> in developmental tumor models by generating Hells conditional knockout osteosarcoma mouse models to examine the role of HELLS in osteosarcoma tumor development.
|
30220967 |
2018 |
|
Astrocytoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Up-regulation of transcription factor E2F1 in astrocytomas and glioblastoma was associated with the progression of gliomas and correlated with LSH expression.
|
28042322 |
2017 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Survival analysis in an independent cohort of 55 RCC patients based on expression in primary RCC showed that TOP2A (hazard ratio [HR] = 4.3, P = .005), HELLS (HR = 3.7, P = .007), ATAD2 (HR = 3.7, P = .019), and TET3 (HR = 2.8, P = .035) represent independent predictors for cancer-specific survival.
|
28069330 |
2017 |
|
Malignant neoplasm of prostate
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
HELLS expression of ≥ 1% occurred in 10% GS < 7, 17% GS 7 and 43% GS >7 prostate cancer (p < 0.001).
|
27191985 |
2016 |
|
Prostate carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
HELLS expression of ≥ 1% occurred in 10% GS < 7, 17% GS 7 and 43% GS >7 prostate cancer (p < 0.001).
|
27191985 |
2016 |
|
Colorectal Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
We identified YAP1 as a direct miR-375 target in CRC and show that HELLS and NOLC1 are down-stream targets.
|
24892549 |
2014 |
|
Retinoblastoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Chromatin remodelers HELLS and UHRF1 mediate the epigenetic deregulation of genes that drive retinoblastoma tumor progression.
|
25338120 |
2014 |
|
Malignant neoplasm of breast
|
0.010 |
Biomarker
|
disease |
BEFREE |
In addition, a decrease of the epigenetic regulator LSH in a breast cancer cell line by siRNA treatment reduced DNA methylation and overcame Pol II stalling, whereas overexpression of LSH in a normal breast epithelial cell line increased DNA methylation and resulted in repression.
|
21880597 |
2011 |
|
Squamous cell carcinoma of oropharynx
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
FOXM1, CEP55, and HELLS were all overexpressed in oropharyngeal squamous cell carcinoma tissue when compared to normal tissue.
|
22109759 |
2011 |
|
Breast Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In addition, a decrease of the epigenetic regulator LSH in a breast cancer cell line by siRNA treatment reduced DNA methylation and overcame Pol II stalling, whereas overexpression of LSH in a normal breast epithelial cell line increased DNA methylation and resulted in repression.
|
21880597 |
2011 |
|
Secondary malignant neoplasm of lymph node
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Low level of HELLS expression was detected in the basal cell layer of the normal oral mucosa, moderate level was seen in dysplasia and high levels in both HNSCC and LnMet.
|
20400365 |
2010 |
|
Malignant transformation
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
We hypothesise that aberrant upregulation of FOXM1 may be inducing genomic instability through a program of malignant transformation involving the activation of CEP55 and HELLS which may facilitate aberrant mitosis and epigenetic modifications.
|
19287496 |
2009 |
|
Mycosis Fungoides
|
0.010 |
Biomarker
|
group |
BEFREE |
Within the first region of deletion at 10q23.33-10q24.1, around microsatellite marker D10S185 (2.77 Mb), 23 genes were identified, including three (KIF11, HHEX, and HELLS) with functions that, if dysregulated, could be critical in MF and SS.
|
15540164 |
2005 |